1x 베팅 주소
News Releases
News releases related to 1x 베팅 주소 central nervous system
2024
1x 베팅 주소
JAMA Psychiatry Publishes Results of 1x 베팅 주소's Phase 3 Trial of Brexpiprazole in Combination with Sertraline in Treatment of Post-Traumatic Stress Disorder (PTSD) in Adults
1x 베팅 주소
1x 베팅 주소 and Jolly Good initiate the sale of FACEDUO Dementia Care Support VR
1x 베팅 주소
1x 베팅 주소 Obtains Exclusive Global Licensing Rights from Ionis to Ulefnersen, a Potential Treatment for Amyotrophic Lateral Sclerosis Caused by Mutations in the Fused in Sarcoma Gene (FUS-ALS)
1x 베팅 주소
1x 베팅 주소 Obtains Additional Indication for Rexulti®in Japan as an Adjunctive Treatment for Agitation Associated with Dementia due to Alzheimer's Disease
1x 베팅 주소
1x 베팅 주소 to Participate in the Orange Innovation Project, Promoted by Japan's Ministry of Economy, Trade and Industry
1x 베팅 주소
1x 베팅 주소 and Jolly Good Launch FACEDUO Dementia Care Support VR
1x 베팅 주소
1x 베팅 주소 Precision Health and Click Therapeutics Announce Launch of Rejoyn™, the First-And-Only Prescription Digital Therapeutic Cleared by the FDA for the Adjunctive Treatment of Major Depressive Disorder (MDD) SymptomsーRejoyn, a first-of-its-kind digital treatment designed to help with cognitive control of emotion, is now available in mobile app stores and can be unlocked with a prescription from a healthcare providerー
1x 베팅 주소
1x 베팅 주소 Present New REXULTI®(brexpiprazole) Post Hoc Efficacy Data Analyses for Agitation Associated with Dementia Due to Alzheimer's Disease at Alzheimer's Association International Conference (AAIC) 2024
1x 베팅 주소
1x 베팅 주소 FDA acceptance of sNDA filing for brexpiprazole in combination with sertraline for the treatment of adults with post-traumatic stress disorder (PTSD)
1x 베팅 주소
1x 베팅 주소 Present Results from Three Clinical Trials of Brexpiprazole in Combination with Sertraline for the Treatment of Post-Traumatic Stress Disorder (PTSD) in Adults
1x 베팅 주소
1x 베팅 주소 to Terminate Development of AVP-786
1x 베팅 주소
1x 베팅 주소 submit sNDA for FDA review of brexpiprazole and sertraline combination as potential treatment for PTSD
1x 베팅 주소
FACEDUOEmotion Recognition Training VRnow available - Support for those with developmental conditions such as autism spectrum disorder (ASD), which makes it difficult to read emotions -
1x 베팅 주소
U.S. Food and Drug Administration (FDA) Clearance of Rejoyn®First Prescription Digital 1x 베팅 주소rapeutic Authorized in 1x 베팅 주소 U.S. for 1x 베팅 주소 Adjunctive Treatment of Major Depressive Disorder (MDD) symptoms
1x 베팅 주소
Abilify Maintena®960mg (aripiprazole) approved in 1x 베팅 주소 EU as 1x 베팅 주소 first once-every-two-months long-acting injectable for 1x 베팅 주소 maintenance treatment of schizophrenia
1x 베팅 주소
1x 베팅 주소 Presented New Data Analyses on the Efficacy of REXULTI®(brexpiprazole) for Agitation Associated with Dementia Due to Alzheimer's Disease
1x 베팅 주소
1x 베팅 주소 and Sumitomo Revise License Agreement - 1x 베팅 주소 holds exclusive rights to develop, manufacture, and commercialize ulotaront and SEP-380135 worldwide -
1x 베팅 주소
1x 베팅 주소 Announces Phase 3 Topline Results of AVP-786 in the Treatment of Agitation Associated with Dementia due to Alzheimer's Disease
1x 베팅 주소
1x 베팅 주소 and Jolly Good to Start Delivery of FACEDUO Content for Family Support of People with Severe Social Withdrawal (Hikikomori) FACEDUO is a virtual reality program for social skills training support
2023
1x 베팅 주소
1x 베팅 주소 Obtains the Additional Indication of Adjunctive Treatment of Major Depressive Disorder for Rexulti®in Japan
1x 베팅 주소
MIREVO®, a New Cognitive Function Testing Application for Dementia Care Support, Obtains Regulatory Approval, a First in Japan
1x 베팅 주소
1x 베팅 주소 Applies in Japan for the Additional Indication for Agitation Associated with Dementia due to Alzheimer's Disease for Rexulti®(brexpiprazole)
1x 베팅 주소
1x 베팅 주소 Pharmaceutical Announces Positive Topline Results from Two Pivotal Phase 3 Trials of Centanafadine as a Treatment for Adolescents and Children with Attention-Deficit/Hyperactivity Disorder (ADHD)
1x 베팅 주소
1x 베팅 주소 Pharmaceutical Enters into Cooperative Agreement with Japan Association of Public Mental Health & Welfare Workers
1x 베팅 주소
1x 베팅 주소 Pharmaceutical and Lundbeck Announce Topline Results from Two Phase 3 Trials of Brexpiprazole as Combination Therapy with Sertraline for the Treatment of Post-Traumatic Stress Disorder in Adults
1x 베팅 주소
1x 베팅 주소 Pharmaceutical to Acquire Mindset Pharma - Strengthens pipeline in the area of psychiatric and neurological disorders -
1x 베팅 주소
Sumitomo Pharma and 1x 베팅 주소 Announce Topline Results from Phase 3 DIAMOND 1 and DIAMOND 2 Clinical Studies Evaluating Ulotaront in Schizophrenia
1x 베팅 주소
1x 베팅 주소 Pharmaceutical announces positive results of phase III trial in Japan showingreduced agitation in patients with Alzheimer's dementia treated with brexpiprazole
1x 베팅 주소
1x 베팅 주소 U.S. Food and Drug Administration (FDA) Approval of supplemental New Drug Application (sNDA) for REXULTI®(brexpiprazole) for 1x 베팅 주소 Treatment of Agitation Associated with Dementia due to Alzheimer's Disease
1x 베팅 주소
1x 베팅 주소 ABILIFY ASIMTUFII®(aripiprazole), 1x 베팅 주소 First, Two-month, Long-acting Injectable (LAI) for 1x 베팅 주소 Treatment of Schizophrenia or Maintenance Mono1x 베팅 주소rapy Treatment of Bipolar I Disorder in Adults
1x 베팅 주소
1x 베팅 주소 Issue Statement on U.S. Food and Drug Administration (FDA) Advisory Committee Meeting on brexpiprazole for the Treatment of Agitation Associated with Alzheimer's Dementia
1x 베팅 주소
1x 베팅 주소 Applies for the Additional Indication of Adjunctive Treatmentof Major Depressive Disorder for Rexulti®(brexpiprazole) in Japan
1x 베팅 주소
1x 베팅 주소 and Schrödinger Announce Single-Target, Drug Discovery Collaboration in Neurology
1x 베팅 주소
1x 베팅 주소 FDA acceptance and priority review of sNDA for brexpiprazole for the treatment of agitation associated with Alzheimer's dementia
2022
1x 베팅 주소
1x 베팅 주소 Announces the Launch in Japan of Auto-Injector Dosage Form for AJOVY®Subcutaneous Injection 225mg for Preventive Treatment of Migraine
1x 베팅 주소
Avanir Pharmaceuticals, Inc. Business Will Be IntegratedInto 1x 베팅 주소 America Pharmaceuticals, Inc. as of January 1, 2023
1x 베팅 주소
1x 베팅 주소 and Jolly Good to Launch FACEDUO, a Virtual Reality Support Program forPatients with Schizophrenia and Their Supporters
1x 베팅 주소
1x 베팅 주소 U.S. FDA Acceptance of New Drug Application forAripiprazole 2-month, Ready-to-Use, Long-acting Injectable to Treat Schizophrenia andBipolar I Disorder in Adults
1x 베팅 주소
1x 베팅 주소 Pharmaceutical announces positive results of phase III trial in Japan for brexpiprazole in the treatment of major depressive disorder
1x 베팅 주소
1x 베팅 주소 Pharmaceutical and Lundbeck present positive results showing reduced agitation in patients with Alzheimer's dementia treated with brexpiprazole at the 2022 Alzheimer's Association International Conference
1x 베팅 주소
1x 베팅 주소 Pharmaceutical and Lundbeck announce positive results showing reduced agitation in patients with Alzheimer's dementia treated with brexpiprazole
1x 베팅 주소
European Medicines Agency Commences Review of Aripiprazole2-Month Long-Acting Injectable for 1x 베팅 주소 Maintenance Treatment of Schizophrenia in Adult Patients Stabilised with Aripiprazole
1x 베팅 주소
1x 베팅 주소 Obtains Approval in Japan for Auto-Injector Dosage Form for AJOVY®Subcutaneous Injection 225 mg for Preventive Treatment of Migraine
1x 베팅 주소
1x 베팅 주소 and Ai-BrainScience Announce Sales Collaboration Agreement for New Cognitive Function Testing Application That Uses Eye Tracking Technology
1x 베팅 주소
1x 베팅 주소 Enters Agreement with Jolly Good for Co-Development and Sales Rights in Japanfor a Social Skills Training Platform Using Virtual Reality in the Psychiatric Field
1x 베팅 주소
1x 베팅 주소 U.S. FDA Approval of Supplemental New Drug Application for REXULTI®(brexpiprazole) to Treat Schizophrenia in Pediatric Patients
2021
1x 베팅 주소
Sumitomo Dainippon Pharma and 1x 베팅 주소 Announce a Worldwide Collaborationand License Agreement for Four Psychiatry and Neurology Compounds
1x 베팅 주소
1x 베팅 주소 to Launch AJOVY®Subcutaneous Injection 225 mg Syringe in Japan
1x 베팅 주소
1x 베팅 주소 Obtains Approval in Japan for Orally-Disintegrating-Dose Form of REXULTI®Tablets
1x 베팅 주소
1x 베팅 주소 reports topline outcomes on a phase II trial that evaluated brexpiprazole for the treatment of borderline personality disorder
1x 베팅 주소
1x 베팅 주소 Files Application in Japan for Approval of Auto-Injector Dosage Form for AJOVY®Subcutaneous Injection 225 mg for Preventive Treatment of Migraine
1x 베팅 주소
AJOVY®Subcutaneous Injection 225 mg Syringe, as a Preventive Treatment of Migraine, Granted Approval in Japan
1x 베팅 주소
1x 베팅 주소 decision to continue phase III clinical trial evaluating brexpiprazole for treatment of agitation in patients with Alzheimer's-type dementia
1x 베팅 주소
1x 베팅 주소 and Perception Neuroscience Announce Collaboration on Development of PCN-101 (R-ketamine) in Japan for Treatment of Depressive Disorders
2020
1x 베팅 주소
1x 베팅 주소's ABILIFY MAINTENA approved for the additional indication of bipolar I disorder in Japan
1x 베팅 주소
1x 베팅 주소 Filed Application in Japan for Approval of Fremanezumab as a Prophylactic Treatment for Migraine
1x 베팅 주소
1x 베팅 주소 Pharmaceutical and Axcelead Drug Discovery Partners announce joint research in CNS indications
1x 베팅 주소
1x 베팅 주소 Announces Positive Top-line Results from Two Phase 3 Studies of Centanafadine for the Treatment of Attention-deficit Hyperactivity Disorder (ADHD) in Adult Patients
1x 베팅 주소
1x 베팅 주소 announces positive top-line results from clinical trials in Japan offremanezumab as a prophylactic treatment for migraine
2019
1x 베팅 주소
1x 베팅 주소 Pharmaceutical and Avanir Pharmaceuticals to Continue Clinical Development ofInvestigational AVP-786 for the Treatment of Agitation in Patients with Alzheimer's Dementia
1x 베팅 주소
1x 베팅 주소's Subsidiary Avanir Pharmaceuticals Reports Top-line Data from Second Phase 3 Trial Evaluating Investigational AVP-786 for the Treatment of Moderate-to-Severe Agitation in Patients with Alzheimer's Dementia
1x 베팅 주소
1x 베팅 주소 Applies for the Additional Indication in Japan of Bipolar Disorder for ABILIFY MAINTENA for Suspended Release Injectable Suspension
1x 베팅 주소
1x 베팅 주소's Subsidiary Avanir Pharmaceuticals Reports Phase 3 Data Evaluating Investigational AVP-786 for the Treatment of Moderate-to-Severe Agitation in Patients with Alzheimer's Dementia
1x 베팅 주소
Notice regarding 1x 베팅 주소 conclusion of co-development/co-promotion activities in Japan for 1x 베팅 주소 anti-epileptic drug "E Keppra"
1x 베팅 주소
Selincro Tablets 10mg Launched in Japan
1x 베팅 주소
1x 베팅 주소 report phase III data evaluating brexpiprazole for the treatment of manic episodes associated with bipolar I disorder
1x 베팅 주소
Avanir 1x 베팅 주소, Inc. Reaches Agreement in Principle with U.S. Department of Justice Regarding NUEDEXTA (dextromethorphan HBr and quinidine sulfate) 20 mg/10 mg capsule
1x 베팅 주소
Selincro (nalmefene) Tablets 10mg Receives Regulatory Approval in Japan
1x 베팅 주소
1x 베팅 주소 and Click Therapeutics Collaborate to Develop and Commercialize Digital Therapeutics for Patients with Major Depressive Disorder
2018
1x 베팅 주소
1x 베팅 주소 subsidiary Avanir and Optinose agree to terminate license agreement for migraine treatment ONZETRA®Xsail®
1x 베팅 주소
1x 베팅 주소 report positive phase II data for the combination treatment of brexpiprazole and sertraline for the treatment of Post-Traumatic Stress Disorder (PTSD)
1x 베팅 주소
1x 베팅 주소 and Proteus Digital Health Announce Expanded Collaboration Agreement to Advanced Digital Medicines for Mental Health
1x 베팅 주소
1x 베팅 주소's Rxulti®(brexpiprazole) approved by 1x 베팅 주소 European Commission
1x 베팅 주소
1x 베팅 주소's Rxulti® (brexpiprazole) receives positive opinion in EUfrom CHMP for the treatment of schizophrenia in adults
1x 베팅 주소
1x 베팅 주소 to Start Third Phase 3 Trial in June to Evaluate Brexpiprazole in the Treatment of Agitation in Patients with Alzheimer's Disease
1x 베팅 주소
REXULTI®Tablets, a New Antipsychotic Drug, Launched in Japan
1x 베팅 주소
1x 베팅 주소 Receives Approval in Japan for the Manufacture and Sale of New Antipsychotic Drug Rexulti®Tablets for Schizophrenia
2017
1x 베팅 주소
1x 베팅 주소 and Proteus Announce the First U.S. FDA Approval of a Digital Medicine System: ABILIFY MYCITE® (aripiprazole tablets with sensor)
1x 베팅 주소
1x 베팅 주소 will Initiate a Third Phase 3 Trial to Evaluate Brexpiprazole in the Treatment of Agitation in Patients with Dementia of the Alzheimer's Type
1x 베팅 주소
1x 베팅 주소 Submits a Japan NDA for Nalmefene, a Drug to Reduce Alcohol Consumption in Alcohol-Dependent Patients
1x 베팅 주소
1x 베팅 주소 Initiation of Two Phase 3 Trials of Brexpiprazole in Patients with Bipolar I Disorder
1x 베팅 주소
ABILIFY MAINTENA® (aripiprazole) for Extended-Release Injectable Suspension Approved by U.S. FDA for Maintenance Mono1x 베팅 주소rapy Treatment of Bipolar I Disorder
1x 베팅 주소
1x 베팅 주소 Submits New Drug Application in Japan for Aripiprazole Sertraline Combination Tablets
1x 베팅 주소
Nalmefene, a Drug Candidate to Reduce Alcohol Consumption, Shows Positive Results from Phase III Trial in Japan
1x 베팅 주소
1x 베팅 주소 and Proteus Digital Heath Resubmit Application to US FDA for First Digital Medicine
1x 베팅 주소
1x 베팅 주소 and Teva Sign Licensing Agreement for Japan on Prophylactic Migraine Drug Candidate Fremanezumab (TEV-48125)
1x 베팅 주소
1x 베팅 주소 Results of Brexpiprazole on Symptoms of Agitation Related to Alzheimer's-type Dementia
1x 베팅 주소
Lundbeck and 1x 베팅 주소's Brexpiprazole for Adult Patients with Schizophrenia Accepted for Review by EMA
1x 베팅 주소
1x 베팅 주소 Pharmaceutical to Acquire Neurovance, Inc. Acquisition of clinical-stage company in ADHD widens 1x 베팅 주소's presence in mental health
1x 베팅 주소
Health Canada Approves 1x 베팅 주소's REXULTI (brexpiprazole) as a Treatment for Schizophrenia in Adults
1x 베팅 주소
1x 베팅 주소 Submits New Drug Application in Japan for Brexpiprazole in the Treatment of Schizophrenia
2016
1x 베팅 주소
FDA Accepts For Review A Supplemental New Drug Application To Expand Labeling Of Abilify Maintena® (aripiprazole) For 1x 베팅 주소 Treatment Of Bipolar I Disorder
1x 베팅 주소
New 1 mg Tablet Dosage of Antipsychotic ABILIFY Available in Japan
1x 베팅 주소
Antipsychotic ABILIFY Gains Approval in Japan for 1x 베팅 주소 Additional Indication of Irritability Associated with Pediatric Autism Spectrum Disorder
1x 베팅 주소
U.S. FDA Approves Labeling Update of REXULTI®(brexpiprazole) for Maintenance Treatment of Schizophrenia in Patients in 1x 베팅 주소 U.S.
1x 베팅 주소
Headline conclusions from 1x 베팅 주소 phase III study of idalopirdine (Lu AE58054) for cognitive symptoms associated with Alzheimer's disease
1x 베팅 주소
"Neupro®Patch", a Dopaminergic, Anti-Parkinsonian Drug,Will Become Available in Japan in an Additional New Dosage, "Neupro Patch 18 mg"
1x 베팅 주소
FDA Issues Complete Response Letter For Digital Medicine New Drug Application
1x 베팅 주소
ABILIFY for Extended Release Injectable Suspension, Used to treat Schizophrenia, Has Received Approval in Japan for Administration at Deltoid Muscle Site
1x 베팅 주소
Anti-epileptic Drug E Keppra®(generic name: levetiracetam) Obtains Additional Indication of Adjunctive 1x 베팅 주소rapy for Generalized Tonic-Clonic Seizures in Japan
1x 베팅 주소
1x 베팅 주소's Subsidiary Avanir Pharmaceuticals Announces U.S. FDA Approval of ONZETRA™Xsail™for 1x 베팅 주소 Acute Treatment of Migraine in Adults
2015
1x 베팅 주소
1x 베팅 주소 Files for Approval in Japan for an Additional Indication for the Antipsychotic ABILIFY: Excitability Associated with Juvenile Autism
1x 베팅 주소
E Keppra®Injectable, to be Launched in Japan on December 1; Will Contribute to Uninterrupted Treatment of Epilepsy Patients Aged 4 and Over with Partial-onset Seizures
1x 베팅 주소
1x 베팅 주소 Pharmaceutical Affiliate Avanir Pharmaceuticals Announces Initiation of Phase III Trial of AVP-786 for Agitation in Patients with Alzheimer's Disease
1x 베팅 주소
U.S. FDA Accepts First Digital Medicine New Drug Application for 1x 베팅 주소 and Proteus Digital Health
1x 베팅 주소
1x 베팅 주소 Pharmaceutical's Subsidiary Avanir Pharmaceuticals Prevails in NUEDEXTA®Patent Appeal Maintaining Exclusivity Through 2026 in 1x 베팅 주소 U.S.
1x 베팅 주소
U.S. 1x 베팅 주소 REXULTI®(brexpiprazole) as Adjunctive Treatment for Adults with Major Depressive Disorder and as a Treatment for Adults with Schizophrenia
1x 베팅 주소
New Treatment Option in Japan for People Living With Schizophrenia - Abilify for Extended-release Injectable Suspension, for Intramuscular Use, Launched on May 25
1x 베팅 주소
Results of Phase III Study of Brexpiprazole in Adult Patients with Schizophrenia Published in American Journal of Psychiatry
1x 베팅 주소
1x 베팅 주소 Granted Approval in Japan for a New Formulation of ABIILIFY - ABILIFY for Extended-release Injectable Suspension, for Intramuscular Use - Indicated for Schizophrenia
1x 베팅 주소
Novel Anti-epileptic Drug E Keppra®Filed in Japan for Additional Indication of Adjunctive 1x 베팅 주소rapy for Generalized Tonic-clonic Seizures
1x 베팅 주소
Novel Anti-epileptic Drug E Keppra®Approved in Japan for Additional Indication as Mono1x 베팅 주소rapy for Partial-onset Seizures, in Addition to Existing Indication as Adjunctive 1x 베팅 주소rapy for 1x 베팅 주소se Seizures
2014
1x 베팅 주소
U.S. FDA Accepts 1x 베팅 주소's Filing for Review of Brexpiprazole for the Treatment of Schizophrenia and as Adjunctive Therapy for the Treatment of Major Depression
1x 베팅 주소
E Keppra®500 mg Injectable For Mono1x 베팅 주소rapy Treatment of Epilepsy Submitted For Regulatory Review in Japan
1x 베팅 주소
1x 베팅 주소 Submit New Drug Application in The US for Brexpiprazole for The Treatment of Schizophrenia and as Adjunctive Therapy for The Treatment of Major Depressive Disorder
1x 베팅 주소
E Keppra®Injectable Receives Marketing Authorization in Japan Will Contribute to Uninterrupted Treatment of Epilepsy Patients Aged Four and Over
1x 베팅 주소
Launch in Japan of Samsca 30 mg Tablet Formulation for Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD), an Orphan Disease
1x 베팅 주소
IBM and 1x 베팅 주소 Develop Transformative Care Coordination Solution
1x 베팅 주소
1x 베팅 주소 Pharmaceutical's Samsca®Approved in Japan as 1x 베팅 주소 World's First Drug 1x 베팅 주소rapy for ADPKD, a Rare Kidney Disease
1x 베팅 주소
Anti-Epileptic Drug E Keppra®Filed in Japan for Additional Indication of Mono1x 베팅 주소rapy for Partial-Onset Seizures
1x 베팅 주소
1x 베팅 주소's Antipsychotic Aripiprazole Awarded the 60th Okochi Memorial Prize
1x 베팅 주소
1x 베팅 주소 Once-Monthly Abilify Maintena™ Approved in Canada for the Maintenance Treatment of Schizophrenia in Stabilized Adult Patients
1x 베팅 주소
1x 베팅 주소 to present new data on brexpiprazole in major depressive disorder (MDD) at European Psychiatry Association 2014 Congress
1x 베팅 주소
1x 베팅 주소 Pharmaceutical Submits Marketing Authorization Application in Japan for Abilify Once-Monthly Injectable Form for the Treatment of Schizophrenia
2013
1x 베팅 주소
European Medicines Agency (EMA) Accepts 1x 베팅 주소's Marketing Authorisation Application (MAA) for Tolvaptan, an Investigational Compound for Autosomal Dominant Polycystic Kidney Disease (ADPKD)
1x 베팅 주소
Lundbeck and 1x 베팅 주소 to Co-Develop a Vaccine, Lu AF20513, Their Third Collaborative Development Project to Tackle Alzheimer's Disease
1x 베팅 주소
1x 베팅 주소's Once-Monthly Abilify Maintena® (Aripiprazole) Now Approved in Europe for Maintenance Treatment of Schizophrenia in Adult Patients Stabilized with Oral Aripiprazole
1x 베팅 주소
Lundbeck and 1x 베팅 주소 Initiate Phase III Clinical Trials on Lu AE58054 as a New Add-On Treatment for Alzheimer's Disease
1x 베팅 주소
1x 베팅 주소 Receive Postive Chmp Opinion In Europe For Abilify Maintena™, A Once-Monthly Injectable For Schizophrenia
1x 베팅 주소
Phase II clinical data show statistically significant improvement for Lu AE58054 as add-on to donepezil, versus donepezil alone, on cognitive symptoms of Alzheimer's disease*1Lundbeck and 1x 베팅 주소 present data at Alzheimer’s Association International Conference 2013
1x 베팅 주소
Two New Formulations of E Keppra®Developed Dry Syrup Obtains Approval; Application Filed for Injectable Formulation Address various needs of patients with epilepsy from 4 years of age and contribute to improvement of compliance with medication
1x 베팅 주소
A New Choice of 1x 베팅 주소rapy for 1x 베팅 주소 Treatment of Depression:ABILIFY® Granted Additional Approval as Adjunctive 1x 베팅 주소rapy for 1x 베팅 주소 Treatment of Depression in Japan
1x 베팅 주소
Antiepileptic Drug E Keppra®Tablet Approved in Japan for Pediatric Epilepsy (Partial-Onset Seizures)
1x 베팅 주소
Study Shows Effects of Treatment with ABILIFY MAINTENA™ (Aripiprazole) on Psychiatric Hospitalization Rates for Patients with Schizophrenia
1x 베팅 주소
1x 베팅 주소 Pharmaceutical's 44-member Employee Dance Group "1x 베팅 주소-Ren" Presented Traditional "Awa-Odori" of Tokushima, Where the Company Originates From, At Copenhagen Sakura Festival Held in Denmark
1x 베팅 주소
"Epi Diary" - An Epilepsy Diary Application for iOS A New Communication Tool for Patients with Epilepsy and 1x 베팅 주소ir Physicians Now Available at https://itunes.apple.com/app/epi-diary/id616736809?Is=1&mt=8
1x 베팅 주소
Lundbeck and 1x 베팅 주소 Further Expand Alliance and Enter Into Collaboration For the Development and Commercialization of Lu AE58054 In Development For Alzheimer's Disease
1x 베팅 주소
1x 베팅 주소 Advancing Rapidly in Central Nervous System Disorders; Expanding Its Existing Collaboration with Lundbeck
1x 베팅 주소
FDA Approves Once-Monthly ABILIFY MAINTENA™ (Aripiprazole) For Extended-Release Injectable Suspension for 1x 베팅 주소 Treatment of Schizophrenia
1x 베팅 주소
1x 베팅 주소 First Transdermal Dopamin Agonist in Japan Neupro®Patch, For Both Parkinson's Disease and Restless Legs Syndrome, To Be Launched on February 26
1x 베팅 주소
1x 베팅 주소 European Medicines Agency (EMA) Approves Aripiprazole (ABILIFY®) for 1x 베팅 주소 Treatment of Moderate to Severe Manic Episodes in Bipolar I Disorder in Adolescents.
2012
1x 베팅 주소
1x 베팅 주소 initiate the regulatory process for aripiprazole (once-monthly) depot formulation in Europe
1x 베팅 주소
1x 베팅 주소 World's Only Transdermal Dopamin Agonist, Neupro®Patch, Approved in Japan for Both Parkinson's Disease and Restless Legs Syndrome
1x 베팅 주소
ABILIFY® ,1x 베팅 주소 First Antipsychotic Agent in Japan Applying for Adjunctive Treatment in Major Depressive Disorder
1x 베팅 주소
UCB Japan Files for Indication of Pediatric Epilepsy (Partial Onset Seizures) for E Keppra®Tablet; New Dry Syrup Formulation Filed at 1x 베팅 주소 Same Time
1x 베팅 주소
The Federal Circuit Decision Affirming the Validity of the Asserted Claims of 1x 베팅 주소's Patent to ABILIFY®
1x 베팅 주소
Results from a Phase 3 Study of Once-monthly Aripiprazole Intramuscular (IM) Depot Formulation for 1x 베팅 주소 Maintenance Treatment of Schizophrenia Presented at APA Annual Meeting
1x 베팅 주소
New Antipsychotic Agent "ABILIFY® OD Tablets" Pursues Agreeability for Patients, Enables easy Adherence
1x 베팅 주소
Antipsychotic Agent ABILIFY® Receives Regulatory Approvals for Additional Indication "Improvement of Manic Symptoms Associated with Bipolar Disorder" and for New Dosage Form "ABILIFY® OD Tablets"
1x 베팅 주소
1x 베팅 주소 Pharmaceutical Files New Drug Application for The Dopamine Agonist Transdermal Patch, Rotigotine Patch, in Japan
1x 베팅 주소
1x 베팅 주소 Pharmaceutical and UCB focus collaboration in the area of Central Nervous System (CNS) disorders
2011
1x 베팅 주소
New Drug Application for 1x 베팅 주소's Once-monthly Aripiprazole Depot Formulation for Maitenance Treatment of Adult Patients With Schizophrenia Accepted for Review by the U.S. Food and Drug Administration
1x 베팅 주소
1x 베팅 주소 PHARMACEUTICAL CO., LTD. AND H. LUNDBECK A/S Sign Historic Agreement to Deliver Innovative Medicines with Focus on Psychiatric Disorders Worldwide
1x 베팅 주소
1x 베팅 주소 Pharmaceutical Confirmed Clinical Efficacy of Rotigotine Transdermal System for Restless Legs Syndrome in Phase III Clinical Study in Japan
1x 베팅 주소
1x 베팅 주소 Pharmaceutical confirmed clinical efficacy of rotigotine trandermal system in Phase III clinical study in patients with advanced Parkinson's disease in Japan
1x 베팅 주소
1x 베팅 주소 Pharmaceutical Co., LTD. Announces Results from a Phase 2 Study of Investigational Product OPC-34712 as Adjunctive Therapy in Adults with Major Depressive Disorder
1x 베팅 주소
ABILIFY®(aripiprazole) Approved for Maintenance Treatment of Bipolar I Disorder as an Adjunct to Ei1x 베팅 주소r Lithium or Valproate Data from 52-week maintenance trial showed superiority of adjunctive ABILIFY versus adjunctive placebo on primary study endpoint
1x 베팅 주소
1x 베팅 주소 Pharmaceutical Files for Additional Indication Regulatory Approval in Japan for ABILIFY®, a Treatment for 1x 베팅 주소 Manic Symptoms Associated with Bipolar Disorder
2010
1x 베팅 주소
Defendants Appeal From Final Judgment in U.S. Abilify®Patent Litigation
1x 베팅 주소
1x 베팅 주소 Prevails in U.S. Abilify®Patent Litigation
1x 베팅 주소
1x 베팅 주소 ANNOUNCES PHASE 3 ARIPIPRAZOLE INTRAMUSCULAR (IM) DEPOT TRIAL INTERIM ANALYSIS REVEALS EFFICACY CRITERIA MET
1x 베팅 주소
1x 베팅 주소 OPENS FIRST OFFICE IN CANADA Important Milestone for Growing North American Pharmaceutical Operations
1x 베팅 주소
Antiepileptic Drug 'E Keppra®Tablet' with New Mechanism of Action Released on September 17
1x 베팅 주소
E Keppra®(levetiracetam) receives regulatory approval in Japan
1x 베팅 주소
GW and 1x 베팅 주소 Agree Three Year Extension to Global Cannabinoid Research Collaboration
2009
1x 베팅 주소
Galenea and 1x 베팅 주소 Announce Second Extension to Schizophrenia Research Collaboration
1x 베팅 주소
U.S. Food and Drug Administration Approves ABILIFY®(aripiprazole) for 1x 베팅 주소 Treatment of Irritability Associated with Autistic Disorder in Pediatric Patients (Ages 6 to 17 Years)
1x 베팅 주소
1x 베팅 주소 and Bristol-Myers Squibb Extend U.S. Agreement for ABILIFY and Establish a Global Oncology Collaboration
1x 베팅 주소
Antipsychotic agent ABILIFY®Oral Solution 0.1% to be Launched on April 10, 2009 in Japan
2008
2006
1x 베팅 주소
BRISTOL-MYERS SQUIBB AND 1x 베팅 주소 PHARMACEUTICAL CO., LTD. ANNOUNCE EXCLUSIVE LICENSING AGREEMENT FOR DIABETES COMPOUND SAXAGLIPTIN IN JAPAN
1x 베팅 주소
Prix Galien awarded to Abilify®(aripiprazole) for medical innovation
1x 베팅 주소
Drug to treat schizophrenia with a new mechanism of action Antipsychotic agent "Abilify®" Available in Japan from June 8
1x 베팅 주소